NeoGenomics

What NeoGenomics does

NeoGenomics is a Fort Myers, Florida-based cancer reference laboratory that provides oncology diagnostic testing services to oncologists, pathologists, hospital systems, academic medical centers, and pharmaceutical/biotech partners. Operating across 13 laboratory locations on two continents (US and Cambridge, UK), the company employs roughly 2,200 people and processes over 1.7 million cancer-related tests annually for more than 40,000 unique providers across approximately 4,400 medical sites, including more than 100,000 NGS tests per year. Its 500+ test menu spans all major modalities — next-generation sequencing (NGS), immunohistochemistry (IHC), flow cytometry, fluorescence in situ hybridization (FISH), and comprehensive genomic profiling (CGP) — covering both solid tumors and hematologic malignancies.

The proprietary technology stack centers on three product families: the RaDaR ST ctDNA-based molecular residual disease (MRD) assay tracking up to 48 tumor-specific variants; the PanTracer portfolio (Tissue, LBx liquid biopsy covering 514 genes, and Pro integrated CGP + IHC); and the Paletrra spatial biology platform using AI-driven whole-slide image analysis. The company also operates an Oncology Data Solutions platform commercializing over 2 million unique patient profiles for real-world evidence, biomarker discovery, and clinical trial matching. Epic Aura EHR integration (April 2026) embeds ordering and results directly into clinical workflow.

Revenue is generated primarily through per-test clinical fees billed to Medicare, Medicaid, and commercial insurance (covering 300+ million lives), with MolDX Medicare reimbursement at $3,289 per PanTracer LBx test. Biopharma services — biomarker discovery, companion diagnostic development, clinical trial support, and MRD testing for pharma — and Oncology Data Solutions data monetization represent secondary, higher-margin revenue streams. Q1 2026 revenue was $187 million (+11% YoY), with 2026 guidance of $797–$803 million; the go-to-market is sales-led via a direct field force targeting oncologists, pathologists, and health systems, complemented by major oncology conferences (ASCO, AACR, ESMO) and the Epic EHR distribution channel.

Name

NeoGenomics

Legal name

NeoGenomics Laboratories, Inc.

Website

https://neogenomics.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

NeoGenomics is a publicly traded US cancer reference laboratory providing 500+ oncology diagnostic tests across NGS, IHC, flow cytometry, FISH, and CGP to over 40,000 providers and 4,400 medical sites, serving oncologists, hospital systems, and biopharma partners.

Ownership category

akta.pro rank

Product category

Oncology Diagnostic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

Keywords

• Cancer diagnostic testing
• Oncology reference laboratory
• Comprehensive genomic profiling
• Molecular residual disease
• Biopharma testing services

Headquarters

HQ city

Fort Myers

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Clinical Testing Services: Revenue from providing oncology diagnostic testing services to healthcare providers including oncologists, pathologists, and hospital systems. Includes over 500 tests across all major modalities (NGS, IHC, flow cytometry, FISH). Revenue grew 14% in Q1 2026 driven by NGS growth of 26%. Average revenue per clinical test was $495 in Q1 2026, up 8%. Revenue from approximately 1.7 million tests annually across more than 4,400 medical sites.
2. Biopharma Services: Services to pharmaceutical and biotech companies including biomarker discovery, companion diagnostics development, clinical trial support, and MRD testing (RaDaR ST for pharma). Supports drug development programs across ADC, bispecifics, and targeted therapies. Non-clinical revenue declined 15% in Q1 2026 due to pharma sector softness.
3. Oncology Data Solutions: Commercialization of the company's large oncology database (2M+ patient profiles) for real-world evidence, clinical trial matching, therapy outcome assessment, and supporting personalized patient care. Revenue generated from biopharma and healthcare partners accessing data insights.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

NeoGenomics is a premier cancer diagnostics company that provides oncology-focused laboratory testing services to healthcare providers and biopharma partners. The company offers over 500 tests spanning next-generation sequencing (NGS), immunohistochemistry (IHC), flow cytometry, fluorescence in situ hybridization (FISH), and comprehensive genomic profiling (CGP) for solid tumors and hematologic malignancies. It also provides proprietary products including RaDaR ST for molecular residual disease detection, the PanTracer portfolio for tissue and liquid biopsy CGP, and a unique Oncology Data Solutions platform covering over 2 million patient profiles.

Product overview

NeoGenomics offers a comprehensive oncology diagnostic portfolio consisting of multiple interconnected testing products and service lines. The core offerings include the RaDaR ST molecular residual disease assay for ctDNA detection, the PanTracer family (PanTracer Tissue, PanTracer LBx, and PanTracer Pro) for comprehensive genomic profiling via tissue and liquid biopsy approaches, and the Neo Comprehensive panels for myeloid disorders. These products are complemented by clinical testing services spanning 500+ tests across all major modalities (NGS, IHC, flow cytometry, FISH), biopharma partnership services, and an Oncology Data Solutions platform. The portfolio enables precision oncology through therapy selection, MRD monitoring, and clinical trial matching.

Differentiator

Problem solved

Functional benefit

Brands

• RaDaR ST: Circulating tumor DNA assay for detecting molecular residual disease across multiple solid tumor types using patient-specific tumor-informed panels
• PanTracer Portfolio
• c-MET CDx
• Paletrra
• Trapelo Health

Products and services

• RaDaR ST Circulating tumor DNA assay for detecting molecular residual disease across multiple solid tumor types, using patient-specific tumor-informed panels with up to 48 tumor-specific variants tracked and a limit of detection of 11 ppm. Available to oncologists for monitoring cancer recurrence.
• PanTracer LBx Liquid biopsy next-generation sequencing panel for advanced-stage pan-solid tumor indications, detecting SNVs, InDels, CNVs, and fusions across 514 genes plus MSI-High and blood tumor mutational burden. Delivered with a 7-day turnaround.
• PanTracer Pro Integrated testing approach combining comprehensive genomic profiling (CGP) with diagnosis-directed immunohistochemistry (IHC) and ancillary testing within a single coordinated order for advanced-stage solid tumors. Covers 517 genes by DNA, 59 genes for CNVs, 55 genes by RNA, with 8-10 day turnaround and automatic liquid biopsy reflex when tissue is insufficient.
• PanTracer Tissue Broad next-generation sequencing panel for pan-solid tumor indications detecting SNVs, InDels, CNVs, RNA fusions and splice variants across 517 genes, plus MSI and TMB, with 8-10 day turnaround.
• c-MET CDx for NSCLC Immunohistochemistry-based companion diagnostic for assessing HGF receptor (c-MET) protein expression to identify non-squamous NSCLC patients eligible for targeted therapy with EMRELIS (telisotuzumab vedotin-tllv).
• Neo Comprehensive - Myeloid Disorders Comprehensive genomic profiling assay using DNA and RNA NGS to detect relevant aberrations for diagnostic evaluation, prognosis, risk stratification, and therapy guidance for a wide range of myeloid disorders.
• Clinical Testing Services Comprehensive oncology-focused testing menu covering over 500 tests across all major methodologies (NGS, IHC, flow cytometry, FISH, comprehensive genomic profiling) for solid tumors and hematologic cancers. Revenue from approximately 1.7 million tests annually across 4,400+ medical sites.
• Biopharma Services Multi-modal solutions for pharma and biotech partners supporting drug development and clinical trials, including biomarker discovery, companion diagnostics development, MRD testing (RaDaR ST for Pharma), and regulatory support across ADC, bispecifics, and targeted therapy programs.
• Oncology Data Solutions Data platform leveraging over 2 million unique patient profiles from over 40,000 unique providers across 4,000 healthcare organizations to support real-world evidence generation, biomarker discovery, clinical trial matching, and therapy outcome assessment for biopharma and healthcare partners.

Quantifiable outcome

• 11% year-over-year revenue growth to $187 million in Q1 2026
• +7 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Epic (Epic Aura)coreTechnology or Integration · 23 April 2026Integration of NeoGenomics' full oncology testing portfolio into Epic Aura EHR, enabling physicians to order cancer tests and view results directly within Epic's clinical workflow across US health systems. Expected to drive 20-30% increase in test adoption per site.
• ConcertAIcoreTechnology or Integration · 6 March 2026Multi-year agreement between ConcertAI and NeoGenomics for AI-driven oncology data and diagnostics. ConcertAI provides AI and real-world data solutions; the partnership integrates clinical genomics data to support biopharma drug development and precision oncology.
• John P. Jack KennyminorOthers · 30 December 2025John P. 'Jack' Kenny, former President and CEO of Meridian Bioscience, appointed to NeoGenomics' Board of Directors. He brings over 30 years of diagnostics and lab services experience including senior roles at Siemens Healthcare, Becton Dickinson, Quest Diagnostics, and Abbott Laboratories. His appointment aims to guide the company's pursuits in NGS and MRD testing.
• BayercoreStrategic or Co-development Partner · 11 December 2025Bayer partnership with NeoGenomics for NTRK testing supporting precision oncology. NeoGenomics provides companion diagnostic testing for NTRK gene fusions to support Bayer's targeted therapy development and patient selection.
• Sylvester Comprehensive Cancer CenterminorStrategic or Co-development Partner · 8 December 2025Partnership with Sylvester Comprehensive Cancer Center (University of Miami) as a data partner for the Sylvester Data Portal, integrating clinical and genomic data from multiple sources including NeoGenomics for cancer research.
• Owkin and France Tissue BankcoreStrategic or Co-development Partner · 29 July 2025Strategic partnership to develop the first IHC-dedicated foundation model for AI-driven ADC diagnostics. The model leverages NeoGenomics' dataset of over 2.5 million digitized pathology images combined with France Tissue Bank's samples curated by over 120 pathologists from 250 healthcare establishments. Goal: enabling precise and reproducible biomarker quantification for patient stratification in precision oncology.
• Adaptive BiotechnologiescoreStrategic or Co-development Partner · 1 January 2025Exclusive multi-year MRD collaboration with Adaptive Biotechnologies for RaDaR ST MRD testing, combining Adaptive's immune sequencing technology with NeoGenomics' circulating tumor DNA capabilities. The collaboration supports biopharma partners developing therapies requiring MRD assessment.
• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 1 January 2024Collaboration with MD Anderson Cancer Center on an interim analysis of RaDaR ST in a colorectal cancer cohort, presented at ASCO 2026.

Scale indicators13 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Guardant Health: Direct competitor in liquid biopsy CGP (Guardant360) and emerging MRD (Guardant Reveal). Comparable on NGS-based oncology testing, biopharma partnerships, and Medicare-covered liquid biopsy reimbursement strategy.
• Foundation Medicine (Roche): Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) for solid tumors. Directly comparable on CGP, biopharma services, and hospital oncology accounts, with deeper global reach via Roche's pharma pipeline.
• Natera: Signatera is the incumbent tumor-informed MRD test, making Natera the closest direct competitor to RaDaR ST. Comparable on MRD clinical evidence generation, biopharma services, and oncology sales force targeting.
• Tempus AI: Oncology diagnostics and data platform spanning NGS profiling, multimodal data, and AI. Directly comparable on CGP, real-world oncology data, biopharma services, and AI-driven insights (e.g., similar Paletrra/AI positioning).
• Caris Life Sciences: Provides MI Profile comprehensive molecular profiling (tissue and liquid) plus Caris Assure MRD. Closely comparable on multi-modal oncology testing menu, MRD offering, and biopharma/CDx partnerships.

Broad incumbents

• Quest Diagnostics: Largest US clinical lab with a sizable oncology offering (including Quest Advanced Oncology). Comparable on test menu breadth, hospital sales coverage, and payer relationships, though Quest spans many non-oncology specialties.
• Laboratory Corporation of America (Labcorp): Major US clinical laboratory with oncology and genomics services. Comparable as a broad clinical laboratory competitor with national hospital and IDN coverage; not as oncology-focused but overlaps on routine and advanced cancer testing.
• Exact Sciences: Larger cancer diagnostics company anchored by Cologuard; expanding into liquid biopsy oncology via the Oncotype/Prevounce and Thrive acquisitions. Broader incumbent with adjacent (not identical) MRD/CGP aspirations.

Emerging players

• Adaptive Biotechnologies: ClonoSeq MRD for hematologic malignancies and immune sequencing platform. NeoGenomics' exclusive MRD partner but also adjacent competitor in clono-/MRD space; comparable on biopharma immuno-oncology partnerships.
• Personalis: Smaller oncology genomics player offering NeXT Personal MRD and tumor profiling assays. Direct overlap on tumor-informed MRD and biopharma CDx services but at a meaningfully smaller scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/NeoGenomics
• YouTubeyoutube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA
• LinkedInlinkedin.com/company/neogenomics-laboratories/mycompany
• Facebookfacebook.com/NeoGenomics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries4 records

Funding overview

Funding rounds9 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoGenomics